Related Experiment Video
Updated: Jun 10, 2026
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 15, 2010
A specific amyloid-beta protein assembly in the brain impairs memory
Sylvain Lesné1, Ming Teng Koh, Linda Kotilinek
1Department of Neurology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Nature
|March 17, 2006
Summary
A soluble amyloid-beta assembly, termed Abeta*56, causes memory loss in aging mice before plaques form. This finding suggests Abeta*56 may be an early driver of cognitive decline in Alzheimer's disease.
Area of Science:
- Neuroscience
- Aging Research
- Molecular Biology
Background:
- Age-related memory decline is often linked to synaptic changes, preceding neuronal loss.
- Alzheimer's disease involves neurodegeneration and amyloid plaques, but early memory deficits may occur without them.
- Tg2576 mice model Alzheimer's disease by expressing a human amyloid precursor protein (APP) variant.
Purpose of the Study:
- Investigate the cause of memory decline in Tg2576 mice lacking neurodegeneration or amyloidosis.
- Identify the specific molecular species responsible for early memory deficits.
- Determine if soluble amyloid-beta assemblies precede plaque formation and cognitive impairment.
Main Methods:
- Utilized Tg2576 mouse model at different age points (young, middle-aged, old).
- Assessed memory function in relation to neuropathology (neuronal loss, amyloid plaques).
- Isolated and characterized soluble amyloid-beta assemblies, specifically Abeta*56.
- Tested the memory-disrupting effects of purified Abeta*56 in young rats.
Main Results:
- Middle-aged Tg2576 mice exhibited memory deficits without neuronal loss or significant plaque formation.
- A 56-kDa soluble amyloid-beta assembly (Abeta*56) was identified as the accumulating species in impaired mice.
- Administering purified Abeta*56 to young rats induced memory impairment.
- Abeta*56 accumulation correlated with memory deficits independently of established neuropathology.
Conclusions:
- Abeta*56 is a key factor causing memory deficits in aging Tg2576 mice.
- This soluble amyloid-beta species impairs memory prior to plaque formation and neuronal loss.
- Abeta*56 represents a potential early therapeutic target for cognitive deficits in Alzheimer's disease.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...